The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II study of MLN-8237 (alisertib), an oral aurora kinase inhibitor, in combination with erlotinib in patients with recurrent or metastatic EGFR wild-type non-small cell lung cancer.
 
James Luke Godwin
No Relationships to Disclose
 
Ranee Mehra
Employment - GlaxoSmithKline (I)
Stock and Other Ownership Interests - GlaxoSmithKline (I)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Genentech; Novartis
Research Funding - Genentech
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Samuel Litwin
No Relationships to Disclose
 
Anthony J. Olszanski
Consulting or Advisory Role - Janssen; Merck; Takeda
Research Funding - Advaxis (Inst); Amgen (Inst); EMD Serono (Inst); Ignyta (Inst); Immunocore (Inst); Incyte (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst); TC Biopharm (Inst)
Travel, Accommodations, Expenses - Takeda
 
Jessica Ruth Bauman
No Relationships to Disclose
 
Hossein Borghaei
Honoraria - Bristol-Myers Squibb; Celgene
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly
Research Funding - Millennium (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly